Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.

Future oncology (London, England) - 1 Aug 2005

Riedel Richard F, Febbo Phillip G

Abstract excerpt

Despite advances in chemotherapeutics, overall survival for advanced lung cancer patients remains poor. Consequently, efforts have focused on the use of targeted therapies to improve response rates and survival. The epidermal growth factor receptor (EGFR) is overexpressed in a variety of cancers, including lung, and may play a critical role in the pathogenesis of disease. Small molecule tyrosine kinase...

Topics

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Clinical Trials as Topic
Drug Resistance, Neoplasm
ErbB Receptors
Gefitinib
Humans
Lung Neoplasms
Mutation
Quinazolines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16556022
DOI: 10.2217/14796694.1.4.461

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-16556022-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.PMID 16556022Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Semantic proximity Read ↗

EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.Semantic proximity Read ↗

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.Semantic proximity Read ↗

Biological and clinical implications of EGFR mutations in lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.Semantic proximity Read ↗

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.Semantic proximity Read ↗

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.Semantic proximity Read ↗

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.Semantic proximity Read ↗

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.Semantic proximity Read ↗

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.